Evidence map›Paper›PMID 42516031›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world.

Heather M Snyder, Malavika P Tampi, Paul S Aisen, Ricardo Allegri, Liana G Apostolova, Alireza Atri, Sheena Aurora, Paulo Caramelli, Lucia Crivelli, Jeffrey Cummings and 27 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease: a cochrane review summary and appraisal for the neurological community.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Heather M SnyderDivision of Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, Illinois, USA.
Malavika P TampiDivision of Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, Illinois, USA.
Paul S AisenEpstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Ricardo AllegriDepartment of Cognitive Neurology, Instituto Neurológico Fleni, Buenos Aires, Argentina.
Liana G ApostolovaIndiana University School of Medicine, Indianapolis, Indiana, USA.
Alireza AtriBanner Health, Phoenix, Arizona, USA.
Sheena AuroraDivision of Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, Illinois, USA.
Paulo CaramelliBehavioral and Cognitive Neurology Unit, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Lucia CrivelliFleni-CONICET, Buenos Aires, Argentina.
Jeffrey CummingsDepartment of Brain Health, University of Nevada, Las Vegas, Nevada, USA.
Bart de StrooperUK Dementia research institute at University College London, KULeuven, Leuven, Belgium.
Nick C FoxDementia Research Centre UCL Institute of Neurology, Greater London, London, UK.
Lea Tenenholz GrinbergDepartments of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
John HardyQueen Square Institute of Neurology, University College London, Greater London, London, UK.
Bruce T LambIndiana University School of Medicine, Indianapolis, Indiana, USA.
Allan LeveyGoizueta Brain Health Institute, Emory School of Medicine, Brookhaven, Georgia, USA.
Oscar LopezDepartments of Neurology, Psychiatry and Clinical & Translational Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Catherine MummeryUniversity College London Hospitals, Greater London, London, UK.
Ricardo NitriniDepartment of Neurology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Sarah PahlkeDivision of Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, Illinois, USA.
Ronald C PetersenMayo Alzheimer's Disease Research Center, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
K Joanne PikeDivision of Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, Illinois, USA.
Anton P PorsteinssonWilliam B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine, University of Rochester School of Medicine and Dentistry, Rochester, Minnesota, USA.
Gil D RabinoviciDepartments of Neurology, Radiology and Biomedical Imaging, Fein Memory and Aging Center, University of California, San Francisco, San Francisco, California, USA.
Michael RafiiEpstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Rema RamanEpstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Marwan N SabbaghAlzheimer's and Memory Disorders Division, Neuropsychiatry Program, Balance Disorders Program at Barrow Neurological Institute, Barrow Neurological Institute, Phoenix, Arizona, USA.
Stephen P SallowayDementia Fund, EQT Life Sciences, Amsterdam, the Netherlands.
Philip ScheltensDepartment of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Jonathan M SchottDementia Research Centre UCL Institute of Neurology, Greater London, London, UK.
Dennis J SelkoeAnn Romney Center for Neurologic Diseases and the Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
Gustavo SevleverFleni-CONICET, Buenos Aires, Argentina.
Reisa SperlingCenter for Alzheimer Research and Treatment, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.
Malu Gamez TanseyIndiana University School of Medicine, Indianapolis, Indiana, USA.
Christopher van DyckDepartments of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, New Haven, Connecticut, USA.
Henrik ZetterbergUniversity of Gothenburg, Mölndal, Sweden.
Maria C CarrilloDivision of Medical and Scientific Relations and Medical Affairs, Alzheimer's Association, Chicago, Illinois, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In response to a Cochrane review (published in April 2026) on the clinical trials of monoclonal antibodies targeting beta amyloid, this perspective outlines a number of critiques. The scientists, methodologists, subject-matter experts, and clinicians on this perspective strongly recommend that the Cochrane editorial board consider a call for editorial response, correction of press materials, or commissioned reply to this review for four overarching reasons: (1) decision to pool antibodies that do and do not clear beta amyloid, (2) decision to include studies from a time when biomarkers of Alzheimer's disease were not available, (3) analytical and methodological limitations of the approach used, (4) conflating the distinct roles and methodological processes of systematic review and guideline methodologies, (5) contextualizing the present critique within the existing evidence-synthesis literature, and (6) mechanistic inference beyond the scope of the presented analyses. Conclusions that may not accurately reflect treatment-specific effects could cause significant downstream clinical and psychosocial harm to those currently undergoing treatment and their family members as well as individuals considering participation in Alzheimer's clinical trials.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, MonoclonalClinical Trials as TopicHumansAmyloid beta-PeptidesAntibodies, MonoclonalAlzheimer's diseaseclinical trialsneurodegenerationsystematic reviewtherapeutic development

Identifiers

PMID42516031
PMCPMC13408703

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.